Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

• Status: Terminated
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure.

PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Comprehensive Cancer Center of Wake Forest University; Wake Forest University Health Sciences
• Treatments: Benazepril; Lisinopril; Losartan; Ramipril

Criteria

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure > 130 OR a diastolic pressure > 80

• Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy

• Creatinine < 2.5

• Potassium < ULN

• Ability to understand and the willingness to sign a written informed consent document

• HIV positive patients are eligible to participate in this study

Exclusion Criteria:

• Patients who are pregnant or nursing due to significant risk to the fetus/infant

• Patients who are unable to take oral medications

• Patients who are currently taking an ACE-Inhibitor or ARB